0001193125-26-208967
SEC filingQ1 revenue declined 48.2% to $21.1M amid market pressures, but operating loss narrowed 62.1% to -$12.5M through 2025 restructuring-driven expense reductions, driving net income to $127.1M from a prior loss.
Standard BioTools Inc. reported Q1 FY2026 results reflecting core operational challenges offset by significant expense discipline from prior restructuring. Revenue of $21.1 million declined 48.2% year-over-year from $40.8 million, primarily due to fluctuations in product demand and manufacturing capacity utilization in response to market conditions, as noted in management discussion. This drove gross profit down 42.7% to $11.3 million, though gross margin held steady at 53.5%, demonstrating resilience in cost management relative to the lower top line.
Operating income improved markedly to a loss of $12.5 million, a 62.1% reduction from the prior $33.0 million loss (operating margin -59.1%). This leverage stemmed directly from 2025 restructuring activities, which reduced R&D and SG&A expenses through lower personnel-related costs. SG&A, comprising sales, marketing, finance, legal, HR, IT, and general management personnel plus professional services, saw particular benefit from these headcount actions, enabling narrower losses despite revenue contraction.
Net income flipped to a $127.1 million profit from a $26.0 million loss, with diluted EPS at $0.33 versus -$0.07—a 588.1% directional change. This headline result highlights non-operating dynamics transforming the bottom line, though core operations remain focused on efficiency gains.
Looking forward, the company plans significant R&D investment to advance products and services, expecting absolute R&D expense increases and variability as a percentage of revenue. Consumables revenue is anticipated to grow via existing customer utilization, installed base expansion, and new offerings, positioning for recovery amid current headwinds.